+19.3%
ARM vs MRNA
+945.0%
-925.7%
-56.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.3% | +13.1% | -18.4% | -5.6% |
| 7D | -18.7% | +20.6% | -39.3% | -19.1% |
| 30D | -36.7% | +27.1% | -63.8% | -37.0% |
| 3M | -31.6% | +353.4% | -385.0% | -36.2% |
| 6M | -5.6% | +446.3% | -451.9% | -16.5% |
| YTD | +75.5% | +776.2% | -700.7% | +47.8% |
| 1Y | +19.3% | +987.9% | -968.6% | -3.9% |
| All | +19.3% | +945.0% | -925.7% | -3.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling